MA42399B1 - Composés inhibiteurs de la voie de signalisation de notch - Google Patents

Composés inhibiteurs de la voie de signalisation de notch

Info

Publication number
MA42399B1
MA42399B1 MA42399A MA42399A MA42399B1 MA 42399 B1 MA42399 B1 MA 42399B1 MA 42399 A MA42399 A MA 42399A MA 42399 A MA42399 A MA 42399A MA 42399 B1 MA42399 B1 MA 42399B1
Authority
MA
Morocco
Prior art keywords
compounds
signaling pathway
notch signaling
inhibit
hair cells
Prior art date
Application number
MA42399A
Other languages
English (en)
Other versions
MA42399A (fr
Inventor
Gaiying Zhao
Julia Marie Clay
Albert Edge
Philip Arthur Hipskind
John C Gill
Bharvin Kumar Patel
Es Helmuth Hendrikus Gerardus Van
Aaron D Wrobleski
Original Assignee
Lilly Co Eli
Audion Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Audion Therapeutics filed Critical Lilly Co Eli
Publication of MA42399A publication Critical patent/MA42399A/fr
Publication of MA42399B1 publication Critical patent/MA42399B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne les composés suivants, ou des sels pharmaceutiquement acceptables de ceux-ci, et des compositions pharmaceutiques contenant lesdits composés utilisables en tant qu'inhibiteurs de la voie de signalisation de notch pour le traitement de cancers désignés, de la surdité neurosensorielle provoquée par la perte de cellules ciliées du système auditif, et pour induire la génération de cellules ciliées du système auditif.
MA42399A 2015-07-07 2016-07-01 Composés inhibiteurs de la voie de signalisation de notch MA42399B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189393P 2015-07-07 2015-07-07
PCT/US2016/040612 WO2017007702A1 (fr) 2015-07-07 2016-07-01 Composés inhibiteurs de la voie de signalisation de notch
EP16741742.7A EP3319967B1 (fr) 2015-07-07 2016-07-01 Composés inhibiteurs de la voie de signalisation de notch

Publications (2)

Publication Number Publication Date
MA42399A MA42399A (fr) 2018-05-16
MA42399B1 true MA42399B1 (fr) 2019-08-30

Family

ID=56507825

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42399A MA42399B1 (fr) 2015-07-07 2016-07-01 Composés inhibiteurs de la voie de signalisation de notch

Country Status (42)

Country Link
US (1) US10450317B2 (fr)
EP (1) EP3319967B1 (fr)
JP (1) JP6571214B2 (fr)
KR (1) KR102078946B1 (fr)
CN (1) CN107849054B (fr)
AR (1) AR105080A1 (fr)
AU (1) AU2016289822B2 (fr)
CA (1) CA2987431C (fr)
CL (1) CL2018000007A1 (fr)
CO (1) CO2018000224A2 (fr)
CR (2) CR20220368A (fr)
CY (1) CY1122024T1 (fr)
DK (1) DK3319967T3 (fr)
DO (1) DOP2018000005A (fr)
EA (1) EA032634B1 (fr)
EC (1) ECSP18000042A (fr)
ES (1) ES2735139T3 (fr)
HK (1) HK1247187B (fr)
HR (1) HRP20191175T1 (fr)
HU (1) HUE044666T2 (fr)
IL (1) IL255726B (fr)
JO (1) JO3491B1 (fr)
LT (1) LT3319967T (fr)
MA (1) MA42399B1 (fr)
MD (1) MD3319967T2 (fr)
ME (1) ME03495B (fr)
MX (1) MX376082B (fr)
MY (1) MY197519A (fr)
NZ (1) NZ737322A (fr)
PE (1) PE20180412A1 (fr)
PH (1) PH12018500047B1 (fr)
PL (1) PL3319967T3 (fr)
PT (1) PT3319967T (fr)
RS (1) RS59115B1 (fr)
SI (1) SI3319967T1 (fr)
SV (1) SV2017005597A (fr)
TN (1) TN2017000495A1 (fr)
TR (1) TR201908683T4 (fr)
TW (1) TWI625332B (fr)
UA (1) UA120539C2 (fr)
WO (1) WO2017007702A1 (fr)
ZA (1) ZA201707858B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
JO3491B1 (ar) 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
JP7033789B2 (ja) 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
US11253193B2 (en) * 2016-11-08 2022-02-22 Cochlear Limited Utilization of vocal acoustic biomarkers for assistive listening device utilization
JP6904612B2 (ja) 2016-12-16 2021-07-21 パイプライン セラピューティクス， インコーポレイテッド 蝸牛シナプス障害を処置する方法
CN110461835A (zh) * 2017-03-24 2019-11-15 诺华股份有限公司 异噁唑甲酰胺化合物及其用途
WO2020016855A1 (fr) * 2018-07-20 2020-01-23 The Hong Kong Polytechnic University Peptides pour l'inhibition spécifique de la voie de signalisation jag1-notch1
MX2021003294A (es) * 2018-09-21 2021-07-15 Novartis Ag Compuestos de isoxazol carboxamida y usos de los mismos.
EP3860562A1 (fr) 2018-10-02 2021-08-11 Frequency Therapeutics, Inc. Compositions pharmaceutiques comprenant des agents thérapeutiques otiques et procédés associés
US20220008433A1 (en) * 2018-11-30 2022-01-13 Massachusetts Eye And Ear Infirmary Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells
SG11202111191YA (en) 2019-04-08 2021-11-29 Frequency Therapeutics Inc Combination of chir99021 and valproic acid for treating hearing loss
WO2021150672A2 (fr) * 2020-01-22 2021-07-29 Beth Israel Deaconess Medical Center, Inc. Biomarqueurs pour troubles du spectre du placenta accreta (pas)
WO2022158610A1 (fr) * 2021-01-20 2022-07-28 Prism BioLab Co., Ltd. Nouveaux composés bicycliques
JP2025512138A (ja) * 2022-04-11 2025-04-16 株式会社 PRISM BioLab 新規七員環縮合化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
KR101169628B1 (ko) 2006-03-27 2012-07-30 에프. 호프만-라 로슈 아게 감마 세크레테아제 저해제로서의 말론아미드 유도체
AU2009212135B2 (en) 2008-02-07 2014-08-21 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
CA2743436C (fr) 2008-11-24 2017-10-31 Massachusetts Eye & Ear Infirmary Voies pour generer des cellules pileuses
WO2012047706A2 (fr) 2010-10-06 2012-04-12 Massachusetts Eye & Ear Infirmary Procédés destinés à favoriser la réinnervation des cellules des cils auditifs
JO3148B1 (ar) * 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
US8716229B2 (en) 2011-11-09 2014-05-06 Massachusetts Eye & Ear Infirmary Osteoprotegerin in neuroprotection
HK1211875A1 (en) * 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
WO2014071275A1 (fr) 2012-11-02 2014-05-08 Genesys Research Institute Compositions et méthodes pour thérapie auditive
JO3491B1 (ar) 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
JP6904612B2 (ja) * 2016-12-16 2021-07-21 パイプライン セラピューティクス， インコーポレイテッド 蝸牛シナプス障害を処置する方法

Also Published As

Publication number Publication date
US20180148456A1 (en) 2018-05-31
IL255726B (en) 2020-10-29
AU2016289822A1 (en) 2017-11-30
TN2017000495A1 (en) 2019-04-12
HRP20191175T1 (hr) 2019-10-04
WO2017007702A1 (fr) 2017-01-12
JP2018520157A (ja) 2018-07-26
CA2987431A1 (fr) 2017-01-12
CN107849054B (zh) 2020-04-28
KR20180011314A (ko) 2018-01-31
MD3319967T2 (ro) 2019-11-30
NZ737322A (en) 2019-05-31
TR201908683T4 (tr) 2019-07-22
KR102078946B1 (ko) 2020-02-19
SV2017005597A (es) 2019-04-04
ES2735139T3 (es) 2019-12-16
CL2018000007A1 (es) 2018-06-29
CO2018000224A2 (es) 2018-04-10
CN107849054A (zh) 2018-03-27
PH12018500047A1 (en) 2018-07-09
EP3319967A1 (fr) 2018-05-16
US10450317B2 (en) 2019-10-22
MX376082B (es) 2025-03-07
LT3319967T (lt) 2019-08-12
UA120539C2 (uk) 2019-12-26
TW201712016A (zh) 2017-04-01
SI3319967T1 (sl) 2019-08-30
JP6571214B2 (ja) 2019-09-04
MY197519A (en) 2023-06-19
JO3491B1 (ar) 2020-07-05
CR20220368A (es) 2022-08-23
TWI625332B (zh) 2018-06-01
HUE044666T2 (hu) 2019-11-28
HK1247187B (en) 2020-01-10
MA42399A (fr) 2018-05-16
PE20180412A1 (es) 2018-03-01
AU2016289822B2 (en) 2018-07-26
IL255726A (en) 2018-01-31
ECSP18000042A (es) 2018-03-31
EP3319967B1 (fr) 2019-05-22
EA032634B1 (ru) 2019-06-28
MX2017016555A (es) 2018-11-09
DOP2018000005A (es) 2018-10-31
DK3319967T3 (da) 2019-07-22
CR20170598A (es) 2018-03-20
PT3319967T (pt) 2019-07-29
ZA201707858B (en) 2020-01-29
ME03495B (fr) 2020-01-20
CY1122024T1 (el) 2020-10-14
EA201792478A1 (ru) 2018-06-29
PL3319967T3 (pl) 2019-10-31
CA2987431C (fr) 2019-11-26
PH12018500047B1 (en) 2021-10-06
RS59115B1 (sr) 2019-09-30
AR105080A1 (es) 2017-09-06

Similar Documents

Publication Publication Date Title
MA42399B1 (fr) Composés inhibiteurs de la voie de signalisation de notch
CY1125202T1 (el) Συνδυασμοι που περιλαμβανουν παραγωγα 5-φαινοξυ-3η-πυριμιδιν-4-ονης και η χρηση αυτων για την προφυλαξη ή αγωγη λοιμωξης απο hiv
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA40219A (fr) Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
MX389597B (es) Inhibidores de cdk2/4/6 de piridopirimidinona.
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
EA201890412A1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
MA39153A1 (fr) Nouveaux composés hétérocycliques
MA45905B1 (fr) Composition pour traiter une blépharite contenant du terpinène-4-ol
MA38207A2 (fr) Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées
MA38280A1 (fr) Composes 1,2,3,4-tetrahydroisoquinoleine substitues inhibiteurs de la proteine arginine-methyltransferase 5